布鲁顿酪氨酸激酶抑制剂诱发心房颤动的机制研究进展

Progress in mechanisms of Bruton′s tyrosine kinase inhibitor-induced atrial fibrillation

布鲁顿酪氨酸激酶(BTK)抑制剂通过靶向抑制B细胞受体通路中的BTK阻碍B细胞相关恶性肿瘤的生长,但部分患者出现与药物相关的心房颤动(AF)。AF作为最常见的心律失常类型之一,研究其发生发展的机制在心脏相关疾病的治疗中十分重要。该文就BTK抑制剂诱导AF发生的机制研究进展作一综述。

Bruton′s tyrosine kinase(BTK)inhibitors can inhibit the growth of B cell-related malignancies by targeting BTK in the B cell receptor pathway.However,during the use of BTK inhibitors,some patients develop drug-related atrial fibrillation(AF).AF is one of the most common types of arrhythmia,and it is very important to study the mechanisms of its occurrence and development in the treatment of heart-related diseases.This paper reviews the progress in mechanisms of BTK inhibitor-induced AF.